-
Cyclosporin A: From Structure to Assay Design
2026-09-30
Cyclosporin A connects cyclophilin biology, calcineurin-NFAT signaling, and mitochondrial pore regulation. This guide translates variant-level structural evidence into better assay selection, controls, and interpretation for immunology and mitochondrial research.
-
2-NBDG Glucose Uptake Assay Kit for HCC
2026-09-30
The 2-NBDG Glucose Uptake Assay Kit provides a rapid, non-radioactive way to connect transporter activity with sorafenib-response phenotypes in hepatocellular carcinoma models. Its single-cell fluorescence readout, PI viability control, and phloretin specificity control help separate altered glucose uptake from cell loss or nonspecific fluorescence.
-
FPH1: Building a Function-First Liver Platform
2026-09-29
FPH1 (BRD-6125) reframes hepatocyte expansion around function, not cell number alone. This thought-leadership article connects functional proliferation assays and iPSC-derived hepatocyte workflows with emerging, light-regulated gene therapy while clearly separating established evidence from future translational opportunities.
-
Transient P1 Unwinding in Adenine Riboswitch Binding
2026-09-29
Wu et al. combined position-selective RNA labeling with stopped-flow fluorescence to resolve ligand-dependent conformational kinetics in the full-length adenine riboswitch. The study identifies a short-lived unwound P1 state and shows that P1 responds before the binding pocket and P4, separating early ligand recognition from later structural stabilization.
-
Carbapenemase Gene Transmission in CREC
2026-09-28
Chen et al. examined carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, combining gene detection, plasmid-transfer experiments, susceptibility testing, and strain fingerprinting. The study shows that blaNDM-1 was frequently plasmid-associated and transferable, supporting a surveillance strategy that evaluates resistance genes, mobile elements, phenotype, and clonality together.
-
Farnesylation-Driven KRAS Condensates in Colon Cancer
2026-09-28
The study proposes that farnesylation at KRAS C185 promotes cytoplasmic condensates that cluster RCE1, support KRAS processing and membrane localization, and amplify tumor-promoting signaling in colon cancer. It also reports that statins, particularly pitavastatin, disrupt this process and can improve response to KRAS G12C inhibition, suggesting a combination strategy that merits further validation.
-
Lassa Virus Spike: pH-Driven Entry and Inhibitor Action
2026-09-27
Katz and colleagues map pH-induced structural changes in the Lassa virus spike that help explain receptor release and preparation for membrane fusion. Their structural and functional analysis also shows how ARN-75039 inhibits viral entry, providing a mechanistic basis for further study of this investigational inhibitor.
-
Etoposide (VP-16): Separating DNA Damage from Senescence
2026-09-26
Etoposide (VP-16) is a powerful DNA-damaging research tool, but its effects can be mistaken for senescence or senolysis if assay endpoints are not separated. This guide connects its topoisomerase II mechanism with a Lactobacillus-derived nanovesicle study to show how to design more interpretable experiments.
-
Açaí Extracts: Hepatocyte Toxicity and DDI Potential
2026-09-25
Raichura and colleagues compared solvent-specific açaí extracts in human hepatocytes and complementary transporter assays, finding extract-dependent, time- and dose-related cytotoxicity but no significant induction of the tested CYP enzymes or transporters. The work highlights why botanical–drug interaction assessment should distinguish cell injury, gene-expression changes, and transporter function rather than treating them as interchangeable measures.
-
Cholecystokinin octapeptide ammonium in assays
2026-09-25
A practical, evidence-aware guide to using Cholecystokinin octapeptide ammonium (SKU C8717) in cell-response experiments. It covers receptor context, formulation constraints, concentration planning, interpretation of atrial ANP findings, and criteria for selecting a research reagent.
-
From PXDN to LDHA: Testing GBM Metabolism
2026-09-24
A translational framework for probing the PXDN–LDHA glycolysis axis in glioblastoma, with practical guidance on nucleic-acid perturbation, rescue experiments, and choosing a low-toxicity lipid transfection reagent.
-
Poly(I:C): TLR3 Agonist for Innate Immunity
2026-09-24
Poly (I:C) is a synthetic double-stranded RNA analog used to stimulate innate immune signaling and interferon responses. Its effects depend on the cell model and delivery route, so it is a research stimulus—not a substitute for viral infection or a universal immune-activation protocol.
-
CD40–STING–TRAF2 Signaling in ESCC TLS
2026-09-23
A 2025 study links tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma with favorable survival and identifies IRF4-high B cells as a prominent immune feature. Its mechanistic experiments propose that CD40 and STING compete for TRAF2, connecting non-canonical NF-κB signaling with B-cell activation and providing testable directions for biomarker and cancer immunotherapy research.
-
ICG001: Precision Control of Wnt/β-Catenin
2026-09-23
Explore how ICG001, a selective Wnt/β-catenin pathway inhibitor, separates CBP-dependent transcription from upstream pathway activation. This article translates recent exosome-mediated osteogenesis findings into a practical framework for cancer, fibrosis, and mechanistic Wnt assays.
-
Cy3 Goat Anti-Rabbit IgG: Evidence-Led Imaging
2026-09-22
Discover how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody supports rigorous fluorescence detection beyond routine staining. This evidence-led guide connects reagent architecture with interpretation of Wnt/β-catenin findings in ulcerative colitis research.